

**Emil J Freireich Leukemia Hematology Grand Rounds, Emil J Freireich Leukemia Hematology Grand Rounds - 1/20/2021, Emil J Freireich Leukemia Hematology Grand Rounds - 1/27/2021, Emil J Freireich Leukemia Hematology Grand Rounds - 2/3/2021, Emil J Freireich Leukemia Hematology Grand Rounds Targeting FLT3 mutant AML- Where do we go from here? - 2/10/2021, Emil J Freireich Leukemia Hematology Grand Rounds Recently Approved AML Drugs in Europe: How Biology Might Be Helpful Frontline? - 2/17/2021, Emil J Freireich Leukemia Hematology Grand Rounds - Evolution Of Epigenetic Therapies in MDS and AML 3/17/2021, Emil J Freireich Leukemia Hematology Grand Rounds Population Genomic Approaches In Myeloid Disease - 4/14/2021, Emil J Freireich Leukemia Hematology Grand Rounds Erythrocytosis: Perspective Of The Hematologist - 4/21/2021, Emil J Freireich Leukemia Hematology Grand Rounds Biology and novel therapy of AML with 3q26.2 lesions and EVI1 overexpression - 5/12/2021, Emil J Freireich Leukemia Hematology Grand Rounds - 5/19/2021, Emil J Freireich Leukemia Hematology Grand Rounds - Primers On Eosinophilic Hematologic Neoplasms - 6/9/2021, Emil J Freireich Leukemia Hematology Grand Rounds Improving Outcomes In Patients Allografted for Acute Myeloid Leukemia - 6/16/2021, Emil J Freireich Leukemia Hematology Grand Rounds - Determinants Of Development And Progression Of Clonal Hematopoiesis - 7/7/2021, Emil J Freireich Leukemia Hematology Grand Rounds - Targeting BCL-2 family proteins in Leukemias - 7/14/2021, Emil J Freireich Leukemia Hematology Grand Rounds - What Is New At ASCO? EHA Brief - 7/21/2021, Emil J Freireich Leukemia Hematology Grand Rounds - CLL: The Role Of T Cells; Update O Ibrutinib In High Risk CLL - 8/4/2021, Emil J Freireich Leukemia Hematology Grand Rounds Understanding CLL Biology Through Mouse Models Of Human Genetics- 8/18/2021, Emil J Freireich Leukemia Hematology Grand Rounds - 10/6/2021, Emil J Freireich Leukemia Hematology Grand Rounds - 10/13/2021, Emil J Freireich Leukemia Hematology Grand Rounds - 10/20/2021, Emil J Freireich Leukemia Hematology Grand Rounds - 10/27/2021, Emil J Freireich Leukemia Hematology Grand Rounds - 11/3/2021, Emil J Freireich Leukemia Hematology Grand Rounds - 11/10/2021, Emil J Freireich Leukemia Hematology Grand Rounds - 11/17/2021, Emil J Freireich Leukemia Hematology Grand Rounds - 11/24/2021, Emil J Freireich Leukemia Hematology Grand Rounds - 12/1/2021, Emil J Freireich Leukemia Hematology Grand Rounds - 12/8/2021, Emil J Freireich Leukemia Hematology Grand Rounds - 12/15/2021, Emil J Freireich Leukemia Hematology Grand Rounds - 12/22/2021, Emil J Freireich Leukemia Hematology Grand Rounds - 12/29/2021, Update on myeloproliferative neoplasms from ASH 2020, Emil J Freireich Leukemia Hematology Grand Rounds Topic Treatment of MDS in 2021: an ASH update, Emil J Freireich Leukemia Hematology Grand Rounds Progress in AML Leukemia - 3/3/2021, Emil J Freireich Leukemia Hematology Grand Rounds - AMLSG: Clinical and Translational Research Projects 3/10/2021, Emil J Freireich Leukemia Hematology Grand Rounds AML From An Australian Perspective - 3/24/2021, Emil J Freireich Leukemia Hematology Grand Rounds IDH Mutation in AML - 4/7/2021, Emil J Freireich Leukemia Hematology Grand Rounds Chimeric Antigen Receptor T-cell Therapy for Hematologic Malignancies - 4/28/2021, Emil J Freireich Leukemia Hematology Grand Rounds - Chimeric antigen receptor T-cell therapy for hematologic malignancies - 5/5/2021, Emil J Freireich Leukemia Hematology Grand Rounds - Dissecting The Mechanism Of Bone Marrow Failure In AML - 6/2/2021, Emil J Freireich Leukemia Hematology Grand Rounds Core Binding Factor AML Making Good Better - 6/23/2021, Emil J Freireich Leukemia Hematology Grand Rounds Cytogenetics And NGS In Routine Diagnostic Workup In Hematology As Supported By AI - 8/11/2021, Emil J Freireich Leukemia Hematology Grand Rounds Progress in Frontline AML Treatment at MDACC - 9/1/2021, Emil J Freireich Leukemia Hematology Grand Rounds - 9/15/2021, Emil J Freireich Leukemia Hematology Grand Rounds - 9/22/2021, Emil J Freireich Leukemia Hematology Grand Rounds - 9/29/2021, TBA- Emil J Freireich Leukemia Hematology Grand Rounds - 1/20/2021**

**1/20/2021 8:00:00 AM to 1/20/2021 9:00:00 AM**

**Online**

**Target Audience:**

Specialties: Leukemia

Professions: Physician (MD or DO), Nurse/APN, Student or Trainee

**[Description:](https://mdanderson.cloud-cme.com/Assets/mdanderson/activities/11867/Brochure_11867.pdf%22%20Download%20Handout%20%22%20%22)**

[Weekly series discussing new research in the field of Leukemia. , Weekly series discussing new research in the field of Leukemia.

Objective(s): 1 Apply new strategies for treating Acute Myeloid Leukemia to improve patient outcomes. 2 Interpret the available data for treatment of intermediate or high-risk Myelofibrosis. 3 Incorporate new options for Myelodysplastic Syndrome in practice.
Location: Online
Specialties: Leukemia

Faculty Disclosures:
Keith Pratz, MD (Membership on advisory committees or review panels, board membership, etc.-Abbvie|Membership on advisory committees or review panels, board membership, etc.-Astellas|Membership on advisory committees or review panels, board membership, etc.-Celgene|Membership on advisory committees or review panels, board membership, etc.-Bristol-Myers Squibb - 02/04/2021)
Download Handout , Weekly series discussing new research in the field of Leukemia.

Objective(s): 1 Apply new strategies for treating Acute Myeloid Leukemia to improve patient outcomes. 2 Interpret the available data for treatment of intermediate or high-risk Myelofibrosis. 3 Incorporate new options for Myelodysplastic Syndrome in practice.
Location: Online
Specialties: Leukemia

Faculty Disclosures:
stephane de Botton, MD, PhD (Membership on advisory committees or review panels, board membership, etc.-Bristol-Myers Squibb|no-Pfizer, Inc. - 02/11/2021)
Download Handout , Weekly series discussing new research in the field of Leukemia.

Objective(s): 1 Apply new strategies for treating Acute Myeloid Leukemia to improve patient outcomes. 2 Interpret the available data for treatment of intermediate or high-risk Myelofibrosis. 3 Incorporate new options for Myelodysplastic Syndrome in practice.
Location: Online
Specialties: Leukemia

Faculty Disclosures:
Hagop Kantarjian, MD (Grant or research support-AbbVie-|Grant or research support-Amgen-|Grant or research support-Ascentage-|Grant or research support-Bristol-Myers Squibb-|Grant or research support-Daiichi Sankyo-|Grant or research support-Immunogen-|Grant or research support-Jazz-|Grant or research support-Pfizer, Inc.-|Grant or research support-Sanofi-Aventis-|Honoraria-AbbVie-|Honoraria-Actinium-|Honoraria-Adaptive Biotechnologies-|Honoraria-Amgen-|Honoraria-Apptitude Health-|Honoraria-Daiichi Sankyo-|Honoraria-Janssen Global-|Honoraria-Novartis AG-|Honoraria-Oxford Biometical-|Honoraria-Pfizer, Inc.-|Honoraria-Takeda Pharmaceuticals, Inc.- - 03/15/2021)
Download Handout , Weekly series discussing new research in the field of Leukemia.

Objective(s): 1 Apply new strategies for treating Acute Myeloid Leukemia to improve patient outcomes. 2 Interpret the available data for treatment of intermediate or high-risk Myelofibrosis. 3 Incorporate new options for Myelodysplastic Syndrome in practice. 4 Utilize and implement new strategies for treating Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia and other hematological cancers in clinical practice.
Location: Online
Specialties: Leukemia

Faculty Disclosures:
Elli Papaemmanuil, PhD (Nothing to disclose - 04/14/2021)
Download Handout , Weekly series discussing new research in the field of Leukemia.

Objective(s): 1 Apply new strategies for treating Acute Myeloid Leukemia to improve patient outcomes. 2 Interpret the available data for treatment of intermediate or high-risk Myelofibrosis. 3 Incorporate new options for Myelodysplastic Syndrome in practice.
Location: Online
Specialties: Leukemia

Faculty Disclosures:
Cristhiam M Hernandez, MD (Cristhiam M Hernandez, MD: Nothing to disclose - 03/26/2021 )
, Weekly series discussing new research in the field of Leukemia.

Objective(s): 1 Apply new strategies for treating Acute Myeloid Leukemia to improve patient outcomes. 2 Interpret the available data for treatment of intermediate or high-risk Myelofibrosis. 3 Incorporate new options for Myelodysplastic Syndrome in practice.
Location: Online
Specialties: Leukemia

Faculty Disclosures:
Kapil N Bhalla, MD (Nothing to disclose - 05/05/2021)
, Weekly series discussing new research in the field of Leukemia.

Objective(s): 1 Apply new strategies for treating Acute Myeloid Leukemia to improve patient outcomes. 2 Interpret the available data for treatment of intermediate or high-risk Myelofibrosis. 3 Incorporate new options for Myelodysplastic Syndrome in practice. 4 Utilize and implement new strategies for treating Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia and other hematological cancers in clinical practice.
Location: Online
Specialties: Leukemia

Faculty Disclosures:
Enrico Tiacci, MD (Nothing to disclose - 05/17/2021)
, Weekly series discussing new research in the field of Leukemia.

Objective(s): 1 Apply new strategies for treating Acute Myeloid Leukemia to improve patient outcomes. 2 Interpret the available data for treatment of intermediate or high-risk Myelofibrosis. 3 Incorporate new options for Myelodysplastic Syndrome in practice.
Location: Online
Specialties: Leukemia

Faculty Disclosures:
Andreas Reiter, MD (Grant or research support-Novartis AG-|Membership on advisory committees or review panels, board membership, etc.-Bristol-Myers Squibb-|Membership on advisory committees or review panels, board membership, etc.-Blueprint-|Membership on advisory committees or review panels, board membership, etc.-Incyte-|Membership on advisory committees or review panels, board membership, etc.-Celgene-|Membership on advisory committees or review panels, board membership, etc.-AOP Pharmaceuticals-|Membership on advisory committees or review panels, board membership, etc.-Deciphera-|Membership on advisory committees or review panels, board membership, etc.-Abbvie-|Clinical trial-Astra Zeneca-|Clinical trial-GlaxoSmithKline- - 05/31/2021)
, Weekly series discussing new research in the field of Leukemia.

Objective(s): 1 Apply new strategies for treating Acute Myeloid Leukemia to improve patient outcomes. 2 Interpret the available data for treatment of intermediate or high-risk Myelofibrosis. 3 Incorporate new options for Myelodysplastic Syndrome in practice.
Location: Online
Specialties: Leukemia

Faculty Disclosures:
Charles Craddock, MD, PhD (Speakers Bureau-JAZZ-|Speakers Bureau-Bristol-Myers Squibb-|Speakers Bureau-Abbvie-|Speakers Bureau-Eurocept-|Membership on advisory committees or review panels, board membership, etc.-Novartis AG- - 06/14/2021)
, Weekly series discussing new research in the field of Leukemia.

Objective(s): 1 Apply new strategies for treating Acute Myeloid Leukemia to improve patient outcomes. 2 Interpret the available data for treatment of intermediate or high-risk Myelofibrosis. 3 Incorporate new options for Myelodysplastic Syndrome in practice.
Location: Online
Specialties: Leukemia

Faculty Disclosures:
Koichi Takahashi, MD (Nothing to disclose - 05/26/2021)
Download Handout , Weekly series discussing new research in the field of Leukemia.

Objective(s): 1 Apply new strategies for treating Acute Myeloid Leukemia to improve patient outcomes. 2 Interpret the available data for treatment of intermediate or high-risk Myelofibrosis. 3 Incorporate new options for Myelodysplastic Syndrome in practice.
Location: Online
Specialties: Leukemia

Faculty Disclosures:
Marina Konopleva, MD, PhD (research funding/clinical trials support, Consulting with honorarium-AbbVie|research funding/clinical trials support, Consulting with honorarium-Genentech, Inc.|research funding/clinical trials support, Consulting with honorarium-Stem Line Therapeutics|research funding/clinical trials support, Consulting with honorarium-Forty Seven|research funding/clinical trials support/ collaborator-Eli Lilly and Company|research funding/clinical trials support/ colaborator-Cellectis|research funding/clinical trials support/ collaborator-ablynx|research funding/clinical trials support/ collaborator-Agios|research funding/clinical trials support/ collaborator-ascentage|research funding/clinical trials support/ collaborator-Astra Zeneca|research funding/clinical trials support/ collaborator-Sanofi-Aventis|Membership on advisory committees or review panels, board membership, etc.-Janssen pharmaceuticals|Stocks or stock options, excluding diversified mutual funds-Reata Pharmaceutical|research funding/clinical trials support/ collaborator-Rafael Pharmaceutical|patent- Research Funding- (Pending) -Novartis |patent- Research Funding- (issued;license)-Eli Lilly and Company|Research Funding- (Issued, Licensed, Royalities) -Reata Pharmaceutical - 02/04/2021)
Download Handout , Weekly series discussing new research in the field of Leukemia.

Objective(s): 1 Apply new strategies for treating Acute Myeloid Leukemia to improve patient outcomes. 2 Interpret the available data for treatment of intermediate or high-risk Myelofibrosis. 3 Incorporate new options for Myelodysplastic Syndrome in practice.
Location: Online
Specialties: Leukemia

Faculty Disclosures:
Hagop M Kantarjian, MD (Grant or research support-AbbVie-|Grant or research support-Amgen-|Grant or research support-Ascentage-|Grant or research support-Bristol-Myers Squibb-|Grant or research support-Daiichi Sankyo-|Grant or research support-Immunogen-|Grant or research support-Jazz-|Grant or research support-Novartis AG-|Grant or research support-Pfizer, Inc.-|Honoraria-AbbVie-|Honoraria-Actinium-|Honoraria-Adaptive Biotechnologies-|Honoraria-Amgen-|Honoraria-Apptitude Health-|Honoraria-BioAscend-|Honoraria-Daiichi Sankyo-|Honoraria-Delta Fly-|Honoraria-Janssen Global-|Honoraria-Novartis AG- - 07/08/2021)
Download Handout

Download Handout , Weekly series discussing new research in the field of Leukemia.

Objective(s): 1 Apply new strategies for treating Acute Myeloid Leukemia to improve patient outcomes. 2 Interpret the available data for treatment of intermediate or high-risk Myelofibrosis. 3 Incorporate new options for Myelodysplastic Syndrome in practice.
Location: Online
Specialties: Leukemia

Faculty Disclosures:
Jan A Burger, MD (Grant or research support-Pharmacyclics, Inc.|Grant or research support-Other-BeiGene|Grant or research support-AstraZeneca|Honoraria-Other-Janssen - 01/20/2021)
Download Handout , Weekly series discussing new research in the field of Leukemia.

Objective(s): 1 Apply new strategies for treating Acute Myeloid Leukemia to improve patient outcomes. 2 Interpret the available data for treatment of intermediate or high-risk Myelofibrosis. 3 Incorporate new options for Myelodysplastic Syndrome in practice.
Location: Online
Specialties: Leukemia

Faculty Disclosures:
Elisa T tenHacken, PhD (Nothing to disclose - 08/10/2021)
Download Handout , Weekly series discussing new research in the field of Leukemia.

Objective(s): 1 Apply new strategies for treating Acute Myeloid Leukemia to improve patient outcomes. 2 Interpret the available data for treatment of intermediate or high-risk Myelofibrosis. 3 Incorporate new options for Myelodysplastic Syndrome in practice.
Location: Online
Specialties: Leukemia

Faculty Disclosures:
Guillermo Garcia-Manero, MD (Nothing to disclose - 01/05/2021)
Download Handout , Weekly series discussing new research in the field of Leukemia.

Objective(s): 1 Apply new strategies for treating Acute Myeloid Leukemia to improve patient outcomes. 2 Interpret the available data for treatment of intermediate or high-risk Myelofibrosis. 3 Incorporate new options for Myelodysplastic Syndrome in practice.
Location: Online
Specialties: Leukemia

Faculty Disclosures:
Hagop Kantarjian, MD (Grant or research support-Other-AbbVie|Grant or research support-Other-Amgen|Grant or research support-Other-Ascentage|Grant or research support-Bristol-Myers Squibb|Grant or research support-Daiichi Sankyo|Grant or research support-Other-Immunogen|Grant or research support-Other-Jazz|Grant or research support-Pfizer, Inc.|Grant or research support-Sanofi-Aventis|Honoraria-Other-AbbVie|Honoraria-Other-Actinium|Honoraria-Other-Adaptive Biotechnologies|Honoraria-Other-Amgen|Honoraria-Other-Apptitude Health|Honoraria-Other-BioAscend|Honoraria-Daiichi Sankyo|Honoraria-Other-Delta Fly|Honoraria-Other-Janssen Global|Honoraria-Novartis AG|Honoraria-Other-Oxford Biometical|Honoraria-Pfizer, Inc.|Honoraria-Takeda Pharmaceuticals, Inc. - 12/29/2020)
Download Handout , Weekly series discussing new research in the field of Leukemia.

Objective(s): 1 Apply new strategies for treating Acute Myeloid Leukemia to improve patient outcomes. 2 Interpret the available data for treatment of intermediate or high-risk Myelofibrosis. 3 Incorporate new options for Myelodysplastic Syndrome in practice.
Location: Online
Specialties: Leukemia

Faculty Disclosures:
Konstanze Döhner, MD (Nothing to disclose - 02/16/2021)
Download Handout , Weekly series discussing new research in the field of Leukemia.

Objective(s): 1 Apply new strategies for treating Acute Myeloid Leukemia to improve patient outcomes. 2 Interpret the available data for treatment of intermediate or high-risk Myelofibrosis. 3 Incorporate new options for Myelodysplastic Syndrome in practice.
Location: Online
Specialties: Leukemia

Faculty Disclosures:
Andrew Wei, MD, PhD (Grant or research support-Abbvie-|Grant or research support-Amgen-|Grant or research support-AstraZeneca-|Grant or research support-Celgene/BMS-|Grant or research support-Novartis AG-|Grant or research support-Servier-|Grant or research support-F. Hoffmann La Roche Ltd.-|Honoraria-Abbvie-|Honoraria-Amgen-|Honoraria-Astellas-|Honoraria-AstraZeneca-|Honoraria-Celgene/BMS-|Honoraria-Genentech, Inc.-|Honoraria-Janssen-|Honoraria-MacroGenics-|Honoraria-Novartis AG-|Honoraria-Pfizer, Inc.-|Honoraria-Servier-|Membership on advisory committees or review panels, board membership, etc.-Abbvie-|Membership on advisory committees or review panels, board membership, etc.-Amgen-|Membership on advisory committees or review panels, board membership, etc.-Astellas-|Membership on advisory committees or review panels, board membership, etc.-AstraZeneca-|Membership on advisory committees or review panels, board membership, etc.-Celgene/BMS-|Membership on advisory committees or review panels, board membership, etc.-Genentech, Inc.-|Membership on advisory committees or review panels, board membership, etc.-Janssen-|Membership on advisory committees or review panels, board membership, etc.-MacroGenics-|Membership on advisory committees or review panels, board membership, etc.-Novartis AG-|Membership on advisory committees or review panels, board membership, etc.-Pfizer, Inc.-|Membership on advisory committees or review panels, board membership, etc.-Servier-|Speakers Bureau-Novartis AG-|Speakers Bureau-Abbvie-|Speakers Bureau-Celgene/BMS-|Consulting Fee-Servier-|Receipt of Intellectual Property Rights/Patent Holder-AW is a former employee of the Walter and Eliza Hall Institute and is eligible for a fraction of the royalty stream related to venetoclax - - 03/19/2021)
Download Handout , Weekly series discussing new research in the field of Leukemia.

Objective(s): 1 Apply new strategies for treating Acute Myeloid Leukemia to improve patient outcomes. 2 Interpret the available data for treatment of intermediate or high-risk Myelofibrosis. 3 Incorporate new options for Myelodysplastic Syndrome in practice.
Location: Online
Specialties: Leukemia

Faculty Disclosures:
Courtney D DiNardo, MD (Membership on advisory committees or review panels, board membership, etc.-Other-Agios |Membership on advisory committees or review panels, board membership, etc.-Other-Celgene|Membership on advisory committees or review panels, board membership, etc.-Other-Abbvie|Stocks or stock options, excluding diversified mutual funds-Other-Notable Labs|Honoraria-Novartis AG|Honoraria-Other-Aprea|Honoraria-Gilead|Honoraria-Other-Foghorn Therapeutics - 12/18/2020)
Download Handout , Weekly series discussing new research in the field of Leukemia.

Objective(s): 1 Apply new strategies for treating Acute Myeloid Leukemia to improve patient outcomes. 2 Interpret the available data for treatment of intermediate or high-risk Myelofibrosis. 3 Incorporate new options for Myelodysplastic Syndrome in practice.
Location: Online
Specialties: Leukemia

Faculty Disclosures:
James Kochenderfer, MD (James Kochenderfer, MD: Grant or research support-Gilead-|Receipt of Intellectual Property Rights/Patent Holder-Gilead-|Grant or research support-Bristol-Myers Squib Aventis- - 04/17/2021 )

Objective(s): 1 Apply new strategies for treating Acute Myeloid Leukemia to improve patient outcomes. 2 Interpret the available data for treatment of intermediate or high-risk Myelofibrosis. 3 Incorporate new options for Myelodysplastic Syndrome in practice.
Location: Online
Specialties: Leukemia

Faculty Disclosures:
James Kochenderfer, MD (James Kochenderfer, MD: Grant or research support-Gilead-|Receipt of Intellectual Property Rights/Patent Holder-Gilead-|Grant or research support-Bristol-Myers Squib Aventis- - 04/17/2021 )
, Weekly series discussing new research in the field of Leukemia.

Objective(s): 1 Apply new strategies for treating Acute Myeloid Leukemia to improve patient outcomes. 2 Interpret the available data for treatment of intermediate or high-risk Myelofibrosis. 3 Incorporate new options for Myelodysplastic Syndrome in practice.
Location: Online
Specialties: Leukemia

Faculty Disclosures:
James Kochenderfer, MD (Grant or research support-Gilead-|Receipt of Intellectual Property Rights/Patent Holder-Gilead-|Grant or research support-Bristol-Myers Squib Aventis- - 04/17/2021)
, Weekly series discussing new research in the field of Leukemia.

Objective(s): 1 Apply new strategies for treating Acute Myeloid Leukemia to improve patient outcomes. 2 Interpret the available data for treatment of intermediate or high-risk Myelofibrosis. 3 Incorporate new options for Myelodysplastic Syndrome in practice.
Location: Online
Specialties: Leukemia

Faculty Disclosures:
Tian Y Zhang, MD, PhD (Nothing to disclose - 05/21/2021)
, Weekly series discussing new research in the field of Leukemia.

Objective(s): 1 Apply new strategies for treating Acute Myeloid Leukemia to improve patient outcomes. 2 Interpret the available data for treatment of intermediate or high-risk Myelofibrosis. 3 Incorporate new options for Myelodysplastic Syndrome in practice.

, Weekly series discussing new research in the field of Leukemia.

Objective(s): 1 Apply new strategies for treating Acute Myeloid Leukemia to improve patient outcomes. 2 Interpret the available data for treatment of intermediate or high-risk Myelofibrosis. 3 Incorporate new options for Myelodysplastic Syndrome in practice.
Location: Online
Specialties: Leukemia

Faculty Disclosures:
Torsten Haferlach, MD (Nothing to disclose - 07/26/2021)
Download Handout , Weekly series discussing new research in the field of Leukemia.

Objective(s): 1 Apply new strategies for treating Acute Myeloid Leukemia to improve patient outcomes. 2 Interpret the available data for treatment of intermediate or high-risk Myelofibrosis. 3 Incorporate new options for Myelodysplastic Syndrome in practice.
Location: Online
Specialties: Leukemia

Faculty Disclosures:
Tapan Kadia, MD (Grant or research support-Bristol-Myers Squibb|Grant or research support-Pfizer, Inc.|Grant or research support-Other-Abbvie|Grant or research support-Other-Amgen|Grant or research support-Genentech, Inc.|Grant or research support-Other-Ascentage|Grant or research support-Other-Cellenkos|Grant or research support-AstraZeneca|Grant or research support-Other-Astellas|Paid consultant-Other-Abbvie|Paid consultant-Genentech, Inc.|Grant or research support-Other-Jazz|Paid consultant-Other-Jazz|Paid consultant-Novartis AG|Paid consultant-Daiichi Sankyo|Paid consultant-Other-Agios|Paid consultant-Pfizer, Inc. - 01/28/2021)
Download Handout , Weekly series discussing new research in the field of Leukemia.

Objective(s):
Location: Online
Specialties: Leukemia

Faculty Disclosures:
Srdan Verstovsek, MD, PhD (Nothing to disclose - 01/15/2021)
Download Handout](https://mdanderson.cloud-cme.com/Assets/mdanderson/activities/11867/Brochure_11867.pdf%22%20Download%20Handout%20%22%20%22)



**Accreditation:**

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**Credit Designation:**

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Commercial Support:**

AstraZeneca Grant - AstraZeneca US

**Faculty & Planner Disclosure:**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Name of commercial interest/Nature of relationship** |
| Abhishek Maiti, MD | Activity Co-Director/Chair |  |
| Naveen Pemmaraju, MD | Activity Co-Director/Chair | Nothing to disclose - 01/07/2021 |
| Farhad Ravandi-Kahani, MD | Activity Director/Chair | Grant or research support-Other-Amgen|Grant or research support-Other-Xencor|Grant or research support-Other-Taiho|Grant or research support-Other-Abbvie|Grant or research support-Other-Astex|Grant or research support-Other-Huctichon|Grant or research support-Other-Prelude|Paid consultant-Other-Celgene|Paid consultant-Other-Bristol Myers Squibb|Paid consultant-Other-AstraZeneca|Paid consultant-Other-Novartis|Paid consultant-Other-Agios|Paid consultant-Other-Pfizer|Paid consultant-Other-Jazz - 12/29/2020 |
| Hagop M Kantarjian, MD | Other Planning Committee Member | Grant or research support-Other-AbbVie|Grant or research support-Other-Amgen|Grant or research support-Other-Ascentage|Grant or research support-Bristol-Myers Squibb|Grant or research support-Daiichi Sankyo|Grant or research support-Other-Immunogen|Grant or research support-Other-Jazz|Grant or research support-Pfizer, Inc.|Grant or research support-Sanofi-Aventis|Honoraria-Other-AbbVie|Honoraria-Other-Actinium|Honoraria-Other-Adaptive Biotechnologies|Honoraria-Other-Amgen|Honoraria-Other-Apptitude Health|Honoraria-Other-BioAscend|Honoraria-Daiichi Sankyo|Honoraria-Other-Delta Fly|Honoraria-Other-Janssen Global|Honoraria-Novartis AG|Honoraria-Other-Oxford Biometical|Honoraria-Pfizer, Inc.|Honoraria-Takeda Pharmaceuticals, Inc. - 12/29/2020 |

**Hardware & Software Requirements:**

If this activity includes a virtual meeting, the technical requirements are as follows:

**System Requirements:**

Internet Connection – broadband wired or wireless (3G or 4G/LTE)

Speakers – built-in or wireless Bluetooth

**Windows:**

Internet Browser – Internet Explorer 11+, Edge 12+, Firefox 27+, Chrome 30+

Operating System – Windows 10 Home, Pro, or Enterprise. S Mode is not supported.

**Apple:**

Internet Browser – Safari 7+, Firefox 27+, Chrome 30+

Operating System macOS 10.9 or later

**Processor Requirements:**

Minimum – Single-core 1GHz or higher

Recommended – Dual-core 2GHz or higher (Intel i3/i5/i7 or AMD equivalent)

**RAM Requirements:**

Minimum – N/A

Recommended – 4GB

**Bandwidth:**

50 - 70kbps (down)

**Supported Tablet and Mobile Devices:**

Surface PRO 2 or higher and running Windows 8.1 or higher

iOS and Android devices

Blackberry devices